DE69833509T2 - Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation - Google Patents
Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation Download PDFInfo
- Publication number
- DE69833509T2 DE69833509T2 DE69833509T DE69833509T DE69833509T2 DE 69833509 T2 DE69833509 T2 DE 69833509T2 DE 69833509 T DE69833509 T DE 69833509T DE 69833509 T DE69833509 T DE 69833509T DE 69833509 T2 DE69833509 T2 DE 69833509T2
- Authority
- DE
- Germany
- Prior art keywords
- alkyl
- oder
- aryl
- und
- ist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 C1C=C*=C*1 Chemical compound C1C=C*=C*1 0.000 description 18
- IKGHIFGXPVLPFD-NSHDSACASA-N CC(N[C@@H](Cc1ccccc1)C(OC)=O)=O Chemical compound CC(N[C@@H](Cc1ccccc1)C(OC)=O)=O IKGHIFGXPVLPFD-NSHDSACASA-N 0.000 description 3
- HIDNBRRMSIYCEM-UHFFFAOYSA-N CC(C(CN)S)=O Chemical compound CC(C(CN)S)=O HIDNBRRMSIYCEM-UHFFFAOYSA-N 0.000 description 1
- PMSSGBHWXUPKOP-UHFFFAOYSA-N CC(C(CS)N)=O Chemical compound CC(C(CS)N)=O PMSSGBHWXUPKOP-UHFFFAOYSA-N 0.000 description 1
- MBHINSULENHCMF-UHFFFAOYSA-N CCC(N(C)C)=O Chemical compound CCC(N(C)C)=O MBHINSULENHCMF-UHFFFAOYSA-N 0.000 description 1
- ZXLYYQUMYFHCLQ-UHFFFAOYSA-N CN(C(c1c2cccc1)=O)C2=O Chemical compound CN(C(c1c2cccc1)=O)C2=O ZXLYYQUMYFHCLQ-UHFFFAOYSA-N 0.000 description 1
- DDIIAJRLFATEEE-UHFFFAOYSA-N CN(C(c1c2cccc1)=O)S2(=O)=O Chemical compound CN(C(c1c2cccc1)=O)S2(=O)=O DDIIAJRLFATEEE-UHFFFAOYSA-N 0.000 description 1
- ULZCOWMSBOJCLT-UHFFFAOYSA-N CN(CC1)CCS1(=O)=O Chemical compound CN(CC1)CCS1(=O)=O ULZCOWMSBOJCLT-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N CN(CCC1)C1=O Chemical compound CN(CCC1)C1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- PJAAXNHOFKYZPR-MUUNZHRXSA-N C[C@@](C(CC1)CCN1C(CC(CC1)CCN1C(N)=O)=O)(c(c(CC1)cc(Cl)c2)c2Br)C(NC2)=C1C=C2Br Chemical compound C[C@@](C(CC1)CCN1C(CC(CC1)CCN1C(N)=O)=O)(c(c(CC1)cc(Cl)c2)c2Br)C(NC2)=C1C=C2Br PJAAXNHOFKYZPR-MUUNZHRXSA-N 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N c1ccc2ncccc2c1 Chemical compound c1ccc2ncccc2c1 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99602797A | 1997-12-22 | 1997-12-22 | |
| US996027 | 1997-12-22 | ||
| US14352998A | 1998-08-28 | 1998-08-28 | |
| US143529 | 1998-08-28 | ||
| US18196998A | 1998-10-29 | 1998-10-29 | |
| US181969 | 1998-10-29 | ||
| PCT/US1998/026224 WO1999032114A1 (en) | 1997-12-22 | 1998-12-21 | Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69833509D1 DE69833509D1 (de) | 2006-04-20 |
| DE69833509T2 true DE69833509T2 (de) | 2006-10-26 |
Family
ID=27385940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69833509T Expired - Lifetime DE69833509T2 (de) | 1997-12-22 | 1998-12-21 | Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1041985B1 (OSRAM) |
| JP (1) | JP4502503B2 (OSRAM) |
| KR (1) | KR100700907B1 (OSRAM) |
| CN (1) | CN1129431C (OSRAM) |
| AR (1) | AR017440A1 (OSRAM) |
| AT (1) | ATE317697T1 (OSRAM) |
| AU (1) | AU756762B2 (OSRAM) |
| BR (1) | BR9814419A (OSRAM) |
| CA (1) | CA2315693C (OSRAM) |
| CL (1) | CL2007001889A1 (OSRAM) |
| CO (1) | CO5080764A1 (OSRAM) |
| CZ (1) | CZ298511B6 (OSRAM) |
| DE (1) | DE69833509T2 (OSRAM) |
| DK (1) | DK1041985T3 (OSRAM) |
| ES (1) | ES2255196T3 (OSRAM) |
| HU (1) | HUP0102473A3 (OSRAM) |
| IL (1) | IL136462A0 (OSRAM) |
| MY (1) | MY137303A (OSRAM) |
| NO (1) | NO326832B1 (OSRAM) |
| NZ (1) | NZ504928A (OSRAM) |
| PE (1) | PE20000042A1 (OSRAM) |
| PT (1) | PT1041985E (OSRAM) |
| SK (1) | SK285584B6 (OSRAM) |
| TW (1) | TW581763B (OSRAM) |
| WO (1) | WO1999032114A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2787327B1 (fr) * | 1998-12-21 | 2003-01-17 | Aventis Pharma Sa | Compositions contenant des inhibiteurs de farnesyle transferase |
| AU1400401A (en) * | 1999-11-09 | 2001-06-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment |
| AU2292801A (en) * | 1999-12-22 | 2001-07-03 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Compositions and methods for treatment of breast cancer |
| EP1261348A2 (en) * | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
| CA2397657A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica Inc. | Farnesyl protein transferase inhibitor combinations with platinum compounds |
| CA2397253A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| CA2397475A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| AU2001239275A1 (en) * | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| WO2001064195A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| AU2002236813A1 (en) * | 2001-01-22 | 2002-07-30 | Schering Corporation | Treatment of malaria with farnesyl protein transferase inhibitors |
| ES2318000T3 (es) * | 2001-02-15 | 2009-05-01 | Janssen Pharmaceutica Nv | Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos. |
| HUP0402401A2 (hu) * | 2001-11-30 | 2005-03-29 | Schering Corp. | Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával |
| EP1453513A1 (en) * | 2001-12-03 | 2004-09-08 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| WO2008022535A1 (fr) * | 2006-08-09 | 2008-02-28 | Tian Jin Tasly Group Co., Ltd. | Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique |
| CN105198758A (zh) * | 2015-09-22 | 2015-12-30 | 湖南大学 | 一种高纯度(z)-他莫昔酚的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047246A (en) * | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
| DE69120430D1 (de) * | 1990-12-18 | 1996-07-25 | Wellcome Found | Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen |
| JP2767176B2 (ja) * | 1992-12-15 | 1998-06-18 | 大塚製薬株式会社 | 抗癌剤 |
| US5637688A (en) * | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
| WO1997005902A1 (fr) * | 1995-08-09 | 1997-02-20 | Banyu Pharmaceutical Co., Ltd. | Composition medicinale |
| CZ292791B6 (cs) * | 1995-12-22 | 2003-12-17 | Schering Corporation | Tricyklické amidy, které se používají pro inhibici G-proteinové funkce a k léčení proliferativních onemocnění |
| US5977163A (en) * | 1996-03-12 | 1999-11-02 | Pg-Txl Company, L. P. | Water soluble paclitaxel prodrugs |
| AU715604B2 (en) * | 1996-04-03 | 2000-02-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JP2000508661A (ja) * | 1996-04-15 | 2000-07-11 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 放射線および化学療法に対する細胞の感作 |
| WO1997038664A2 (en) * | 1996-04-18 | 1997-10-23 | Merck & Co., Inc. | A method of treating cancer |
| EP0934270A1 (en) * | 1996-05-30 | 1999-08-11 | Merck & Co., Inc. | A method of treating cancer |
| US6337992B1 (en) * | 1997-01-29 | 2002-01-08 | Philips Medical Systems Technologies Ltd. | Predictive bolus tracking |
| HUP0004326A3 (en) * | 1997-02-18 | 2003-07-28 | Canji Inc San Diego | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
-
1998
- 1998-12-21 BR BR9814419-7A patent/BR9814419A/pt not_active Application Discontinuation
- 1998-12-21 CZ CZ20002236A patent/CZ298511B6/cs not_active IP Right Cessation
- 1998-12-21 AR ARP980106565A patent/AR017440A1/es unknown
- 1998-12-21 PE PE1998001263A patent/PE20000042A1/es not_active Application Discontinuation
- 1998-12-21 CA CA2315693A patent/CA2315693C/en not_active Expired - Fee Related
- 1998-12-21 AT AT98963829T patent/ATE317697T1/de not_active IP Right Cessation
- 1998-12-21 PT PT98963829T patent/PT1041985E/pt unknown
- 1998-12-21 CO CO98075842A patent/CO5080764A1/es unknown
- 1998-12-21 SK SK898-2000A patent/SK285584B6/sk not_active IP Right Cessation
- 1998-12-21 EP EP98963829A patent/EP1041985B1/en not_active Expired - Lifetime
- 1998-12-21 HU HU0102473A patent/HUP0102473A3/hu unknown
- 1998-12-21 JP JP2000525105A patent/JP4502503B2/ja not_active Expired - Fee Related
- 1998-12-21 TW TW087121355A patent/TW581763B/zh not_active IP Right Cessation
- 1998-12-21 DK DK98963829T patent/DK1041985T3/da active
- 1998-12-21 NZ NZ504928A patent/NZ504928A/xx unknown
- 1998-12-21 WO PCT/US1998/026224 patent/WO1999032114A1/en not_active Ceased
- 1998-12-21 KR KR1020007006938A patent/KR100700907B1/ko not_active Expired - Fee Related
- 1998-12-21 MY MYPI98005809A patent/MY137303A/en unknown
- 1998-12-21 ES ES98963829T patent/ES2255196T3/es not_active Expired - Lifetime
- 1998-12-21 AU AU19072/99A patent/AU756762B2/en not_active Ceased
- 1998-12-21 CN CN98813742A patent/CN1129431C/zh not_active Expired - Fee Related
- 1998-12-21 DE DE69833509T patent/DE69833509T2/de not_active Expired - Lifetime
- 1998-12-21 IL IL13646298A patent/IL136462A0/xx unknown
-
2000
- 2000-06-21 NO NO20003229A patent/NO326832B1/no not_active IP Right Cessation
-
2007
- 2007-06-27 CL CL2007001889A patent/CL2007001889A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60032226T2 (de) | Verfahren zur induktion von krebszellentod und tumorregression | |
| US6333333B1 (en) | Methods for treating proliferative diseases | |
| DE69625518T2 (de) | Wirkstoff zur behandlung neurodegenerativer störungen | |
| DE69329073T2 (de) | In liposomen verkapseltes taxol und verwendungsverfahren | |
| DE60216139T3 (de) | Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen | |
| DE19814838C2 (de) | Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung | |
| DE60130017T2 (de) | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität | |
| DE69017302T2 (de) | Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten. | |
| DE69821520T2 (de) | Verwendung von alkylierten iminozuckern zur behandlung von multipler medikamentenresistenz | |
| DE60214846T2 (de) | Verwendung von mGLuR5 antagonists zur Herstellung von Medikamenten zur Behandlung von empfindlichen X Syndrome, Autismus und geistiger Zurückgebliebenheit | |
| DE69628645T2 (de) | Benzimidazolderivaten-enthaltende pharmazeutische zusammensetzungen zur inhibierung des krebswachstums | |
| JP4502503B2 (ja) | 増殖性の疾患を処置するためのベンゾシクロヘプタピリジン化合物および抗腫瘍剤の組合せ | |
| DE3686622T2 (de) | Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen. | |
| WO2002020521A1 (de) | Verwendung von indolderivaten zur behandlung von erkrankungen des zentralen nervensystems | |
| DE19542281A1 (de) | Verwendung von Epinastin für die Behandlung von Schmerzen | |
| DE68923151T2 (de) | Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen. | |
| DE69531722T2 (de) | Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten | |
| DE60316297T2 (de) | Verbindungen, die zur behandlung von erkrankungen, die auf antiangiogene therapie ansprechen, nützlich sind | |
| DE68907392T2 (de) | Dysmnesie modifizierende Arzneimittel. | |
| EP0859613B1 (de) | Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen | |
| DE69919789T2 (de) | Loratadin zur Verwendung als Antiarrhythmikum | |
| DE60011060T2 (de) | Virus behandlung | |
| DE3779991T2 (de) | Dioxopiperidin-derivate enthaltende anxiolytische zusammensetzungen. | |
| DE60318561T2 (de) | Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie | |
| DE60110628T2 (de) | Antiphlogistische mittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |